2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement
Gold L, Gottlieb A, Armstrong A, Alkousakis T, Bissonnette R, Langley R, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao L, Gordon K, Merola J, Lebwohl M, Strober B. SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement. British Journal Of Dermatology 2025, ljaf327. PMID: 40875818, DOI: 10.1093/bjd/ljaf327.Peer-Reviewed Original ResearchLower body surface areaBody surface areaBaseline body surface areaPhysician global assessmentProportion of participantsIGA 0Plaque psoriasisSecondary endpointsModerate plaque psoriasisPlacebo-controlled studyBaseline to weekEffect of guselkumabClinical trial resultsPlacebo groupPrimary endpointModerate psoriasisStatistically significant improvementPsoriasis AreaPhase 3bGuselkumabAdverse eventsSite involvementClinical studiesPlaceboPASIBenefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study
Armstrong A, Strober B, Gisondi P, Orroth K, Cordey M, Kent S, Deignan C, Jardon S, Hernandez R, Brookhart M, Stein Gold L. Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study. Dermatology And Therapy 2025, 15: 2911-2923. PMID: 40767996, PMCID: PMC12454763, DOI: 10.1007/s13555-025-01466-3.Peer-Reviewed Original ResearchBody surface areaApremilast initiationTreatment initiationTopical treatmentMethodsThis retrospective cohort studyLimited skin involvementOral systemic treatmentRetrospective cohort studyCumulative disease burdenBody surface area valuesSystemic therapyTopical therapySkin involvementSystemic treatmentRetrospective studyApremilastCohort studyEarly initiationBSA valuesLate initiationPatientsPsoriasisRelative riskTreatment groupsDisease burdenReal-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
Strober B, Patel M, Kaldas M, St. John G, Photowala H, Sima A, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatology And Therapy 2025, 15: 2409-2421. PMID: 40593269, PMCID: PMC12354662, DOI: 10.1007/s13555-025-01474-3.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexBody surface areaDermatology Life Quality IndexPatient-reported outcomesSkin clearancePlaque psoriasisSkin involvementPsoriasis symptomsFailure of topical therapyLevels of skin clearanceCorEvitas Psoriasis RegistryTreat-to-target goalsBaseline body surface areaInterleukin-23 inhibitorArea Severity IndexDermatology Life Quality Index scoresLife Quality IndexPsoriasis RegistrySystemic therapyTopical therapyConclusionIn patientsTherapy criteriaInterleukin-23Retrospective studyRisankizumabNational Estimates and Outcomes for Supplemental Home Oxygen Therapy Injuries—A Burn Care Quality Platform Analysis
Sheckter C, Stanton E, Klas K, Phillips B, Coffey R, Savetamal A, Wibbenmeyer L. National Estimates and Outcomes for Supplemental Home Oxygen Therapy Injuries—A Burn Care Quality Platform Analysis. Journal Of Burn Care & Research 2025, iraf087. PMID: 40394868, DOI: 10.1093/jbcr/iraf087.Peer-Reviewed Original ResearchTotal body surface areaNational estimatesIncidence rateOdds of discharge homeHome oxygen therapyTargeted prevention strategiesOxygen therapyBurn admissionsInhalation injuryIncidence of admissionPublic health problemTotal body surface area burnHome oxygen usePoisson regressionInjury characteristicsInjury descriptionInpatient mortalityPrevention strategiesBody surface areaInpatient outcomesDischarged homeHealth problemsNational averagePatient demographicsAnnual increaseTralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg A, Shahriari M, Cameron M, Payette M, Dasilva D, Damiani G, Herman E, Eminger L, Issa N, Rodriguez A, Del Rosso J, Kang Y, Cohen J, Bunick C. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 16-19. PMID: 40538523, PMCID: PMC12175839.Peer-Reviewed Original ResearchInvestigator's Global AssessmentAdverse eventsFood and Drug AdministrationAtopic dermatitisInterleukin-4Alternative therapiesSwitching to alternative therapiesSurface area of involvementDiscontinuation of dupilumabDiscontinuation of treatmentT cell populationsChronic inflammatory skin conditionMulti-center case seriesUnited States Food and Drug AdministrationStates Food and Drug AdministrationBody surface areaOptimal clinical outcomesInflammatory skin conditionAD signsTargeting interleukins 4Area of involvementSystemic treatmentT cellsCase seriesClinical outcomesDeep learning-enabled, computed-tomography-based race- and sex-specific epicardial adipose tissue thresholds for cardiovascular risk stratification
Buchwald M, Shanbhag A, Miller R, Zhang W, Michalowska A, Killekar A, Lemley M, Kavanagh P, Fujito H, Liang J, Builoff V, Knight S, Einstein A, Miller E, Feher A, Sinusas A, Chareonthaitawee P, Bullock-Palmer R, Di Carli M, Berman D, Dey D, Slomka P. Deep learning-enabled, computed-tomography-based race- and sex-specific epicardial adipose tissue thresholds for cardiovascular risk stratification. Progress In Biomedical Optics And Imaging 2025, 13410: 1341011-1341011-7. DOI: 10.1117/12.3047613.Peer-Reviewed Original ResearchEpicardial adipose tissueAmount of epicardial adipose tissueComputed tomography attenuation correctionVolume of epicardial adipose tissueSex-specific thresholdsMyocardial infarctionCardiac sizeFollow-upEAT valuesEpicardial adipose tissue densityFamily history of coronary artery diseaseHistory of coronary artery diseaseHeart sizeLeft ventricle sizeBody surface areaNonfatal myocardial infarctionBody mass indexCoronary artery diseaseRisk of deathCardiovascular risk stratificationCigarette smoking statusPrognostic valueRetrospective studyRisk stratificationVentricle size573 Feasibility of an Unfunded Multicenter Trial Group for Older Adult Burn Patients: A Retrospective Study
Nosanov L, Savetamal A, Reynolds J, Bhavsar D, Miotke S, Johnston M, Wibbenmeyer L, Galet C, Hill D, Higginson S, Chin T, Long A, Baker E, Hamm H, Lacey A, Paine R, Tedesco D, Tejiram S, Jeschke M, Romanowski K. 573 Feasibility of an Unfunded Multicenter Trial Group for Older Adult Burn Patients: A Retrospective Study. Journal Of Burn Care & Research 2025, 46: s158-s159. PMCID: PMC11958010, DOI: 10.1093/jbcr/iraf019.202.Peer-Reviewed Original ResearchAdult burn patientsOlder burn patientsLength of hospital stayRetrospective pilot studyBurn patientsTrial groupRetrospective studyHospital stayMedian length of hospital staySingle-center studyTotal body surface areaBurn patient populationMedian time to wound healingTime to wound healingBody surface areaIn-Hospital MortalityMedian burn sizePilot studyMedian BMIIQR 6Median ageClinical outcomesOlder adultsICU stayIQR 5
2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 10: 22-27. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regionsReactive Infectious Mucocutaneous Eruption with Extensive Cutaneous Involvement
Anderson Z, Fotouhi A, Tolliver S, Mehregan D. Reactive Infectious Mucocutaneous Eruption with Extensive Cutaneous Involvement. Clinical Dermatology Review 2024, 8: 256-259. DOI: 10.4103/cdr.cdr_109_23.Peer-Reviewed Original ResearchSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world studyPatient-specific ascending aortic intervention criteria
Kalogerakos P, Zafar M, Li Y, Ellauzi H, Mukherjee S, Ziganshin B, Rizzo J, Elefteriades J. Patient-specific ascending aortic intervention criteria. European Journal Of Cardio-Thoracic Surgery 2024, 65: ezae162. PMID: 38632077, DOI: 10.1093/ejcts/ezae162.Peer-Reviewed Original ResearchAdverse aortic eventsRisk of adverse eventsAortic eventsAortic rootAneurysm patientsAscending aortaAdverse eventsIncreased risk of adverse eventsThoracic aortic aneurysm patientsAscending Aortic AneurysmHigher risk of adverse eventsAortic aneurysm patientsAscending thoracic aortic aneurysm patientsBody surface areaGeneral populationPersonalized risk stratificationAortic diameterAneurysm locationRisk stratificationAortic aneurysmIncreased riskAscending diameterPatientsHigh riskZ-score
2023
American Burn Association Clinical Practice Guidelines on Burn Shock Resuscitation
Cartotto R, Johnson L, Savetamal A, Greenhalgh D, Kubasiak J, Pham T, Rizzo J, Sen S, Main E. American Burn Association Clinical Practice Guidelines on Burn Shock Resuscitation. Journal Of Burn Care & Research 2023, 45: 565-589. PMID: 38051821, DOI: 10.1093/jbcr/irad125.Peer-Reviewed Original ResearchBurn shock resuscitationClinical practice guidelinesResuscitation fluid volumeShock resuscitationFresh frozen plasmaPICO questionPractice guidelinesEarly continuous renal replacement therapyContinuous renal replacement therapyHigh-dose vitamin CTotal body surface areaAcute fluid resuscitationOutcomes of survivalRenal replacement therapyComputer decision support softwareFluid volumeBody surface areaSystematic literature searchHuman albumin solutionResuscitation volumeLevels of screeningFluid resuscitationUrine outputWeak recommendationReplacement therapyInfluence of birth weight on later life cardiovascular structure, function and disease: unpacking influences from direct genetic effects versus intrauterine programming
Ardissino M, Slob E, Rayes B, Morley A, Raisi-Estabragh Z, De Marvao A, Williamson C, Rogne T, Burgess S, Ng F. Influence of birth weight on later life cardiovascular structure, function and disease: unpacking influences from direct genetic effects versus intrauterine programming. European Heart Journal 2023, 44: ehad655.2377. DOI: 10.1093/eurheartj/ehad655.2377.Peer-Reviewed Original ResearchCoronary artery diseaseFetal genetic effectsLow ejection fractionSystolic blood pressureBody mass indexBirth weightArtery diseaseAtrial fibrillationCardiovascular diseaseHigh riskMendelian randomisationEjection fractionBlood pressureMass indexRisk factorsGestational age-adjusted birth weightCardiac structureAge-adjusted birth weightHigher systolic blood pressureLater-life cardiovascular diseaseCardinal risk factorCardiometabolic risk factorsHigh birth weightLife cardiovascular diseaseBody surface area41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials
Strober B, Kircik L, Green L, Lockshin B, Brown P, Tallman A. 41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials. Journal Of The American Academy Of Dermatology 2023, 89: ab92. DOI: 10.1016/j.jaad.2023.07.371.Peer-Reviewed Original ResearchPS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
Warren R, Strober B, Lebwohl M, Foley P, Langley R, Davis L, Hoepken B, Szilagyi B, Ciaravino V, Bewley A. PS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: ljad113.366. DOI: 10.1093/bjd/ljad113.366.Peer-Reviewed Original ResearchOpen-label extensionBody surface areaSevere plaque psoriasisWeek 16Plaque psoriasisOpen-label extension trialTreatment-related adverse eventsDermatology Life Quality IndexPASI 90 responseMaintenance of efficacyHealth-related qualityYear 3Long-term efficacyLife Quality IndexLack of efficacyYear 1HRQoL benefitsNonresponder imputationOLE entryPsoriasis AreaResponder rateAdverse eventsWeek 24Study treatmentAnalysed patientsImpact of Age and Sex on Left Ventricular Remodeling in Patients With Aortic Regurgitation
Akintoye E, Saijo Y, Braghieri L, Badwan O, Patel H, Dabbagh M, El Dahdah J, Jellis C, Desai M, Rodriguez L, Grimm R, Griffin B, Popović Z. Impact of Age and Sex on Left Ventricular Remodeling in Patients With Aortic Regurgitation. Journal Of The American College Of Cardiology 2023, 81: 1474-1487. PMID: 37045517, DOI: 10.1016/j.jacc.2023.02.037.Peer-Reviewed Original ResearchConceptsSmaller LV volumesAdverse eventsAortic regurgitationBody surface areaOlder patientsYounger patientsLV volumesImpact of ageLV remodelingSerial evaluationLV end-systolic volumeLV end-diastolic volumeSevere aortic regurgitationChronic aortic regurgitationLeft ventricular remodelingEnd-diastolic volumeEnd-systolic volumeLower LV volumesAdult patientsConsecutive patientsMain endpointVentricular dimensionsVentricular remodelingCurrent guidelinesPatientsBimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley R, Warren R, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: 749-759. PMID: 36967713, DOI: 10.1093/bjd/ljad035.Peer-Reviewed Original ResearchConceptsOngoing open-label extensionSevere plaque psoriasisBody surface areaDermatology Life Quality IndexWeek 16Plaque psoriasisNonresponder imputationPASI 100Investigator's Global Assessment 0/1Open-label extension trialDLQI 0/1 responsePASI 90 respondersOpen-label extensionHealth-related qualityLong-term efficacyLife Quality IndexLong-term treatmentLoss of responseYear 3Absolute PASIPASI 90Efficacy outcomesClinical responsePsoriasis AreaExtension trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply